🚨 Tactical setup firing right now

Momentum is BACK...

March 28, 2025

Here’s a quick setup I’m watching today that’s got some serious momentum behind it. I’ve been digging into the science too — some wild stuff is happening in cancer treatment right now. Check it out and see what you think.

TODAY’S TOP ALERT! 

 Qualigen Therapeutics (Nasdaq: QLGN)

Happy Friday!

We’re rounding off another tumultuous week in the markets, but if things hold today, stocks could end the week up for a change.

The big thing on investors’ radars today is the PCE price index reading for February, which will give us a better idea of where inflation is heading.

I’m looking at a few different plays today, but as promised, below is a “tactical trade” idea I think is especially promising.

My last two “tactical” ideas have each made double-digit gains the day I alerted them…

Both stocks had been on solid runs — one had nearly doubled in the prior month, and the other was up 45% in the prior two weeks — in the face of incredible market turmoil.

*Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically.

That momentum carried them higher on the days of my alerts. Here was yesterday’s:

It was another MONSTER you got to watch all the way from the starting line.

In fact, it even touched $4.30 this morning in pre-market trading, which puts the peak move over 40% higher from yesterday’s opening price.

Pretty spectacular, if you ask me.

My alert today is on a similar setup…

Go ahead and pull up Qualigen Therapeutics (QLGN) on your trading platform.

As you can see, it’s up nearly 30% over the past two weeks, and yesterday was especially impressive, with a 14% gain on the day.

It’s looking good in the pre-market as well, and today could be another big day for the stock.

👉  QLGN is TODAY’S #1 ALERT 👈

Here are some things I found in my research…

These days, QLGN is a clinical-stage therapeutics company, but it was founded in 1996 as a diagnostics company.

It divested itself of its diagnostics business in July 2023 with the sale of the FastPack® line for approximately $5 million that it put toward its therapeutics pipeline.

Now it is focused especially on developing treatments for adult and pediatric cancer, working with prominent investigators at University College London and the University of Louisville.

It describes its lead compound, QN-302, as “a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.”

It notes that “such binding could, by stabilizing the G4s against ‘unwinding,’ help inhibit cancer cell proliferation.”

The compound has received an Orphan Drug Designation from the FDA for the intended indication of pancreatic cancer, the third-deadliest cancer in the US.

QLGN has found that “Mice treated with QN-302 have shown longer survival duration and greater tumor shrinkage in pancreatic cancer in vivo xenograft and genetic models vs. historically standard of care gemcitabine.”

Right now, the company is putting QN-302 through a Phase 1 trial for treatment of advanced or metastatic solid tumors, and it has initially dosed four patients.

The company has done posters, publications, and presentations at 2022, 2023, and 2024 annual and special meetings of the American Association for Cancer Research (AACR).

QLGN’s other major candidate is its Pan-RAS Inhibitor Platform.

The company explains that “RAS is the most common cancer oncogene [a mutated gene that can cause cancer], present in more than 30% of all cancers”

QLGN has a family of investigational compounds that “are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins.”

In theory, this mechanism of action “may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers.” [emphasis added]

None of the candidate compounds has yet gone to clinical trial, but QLGN has done posters, publications, and presentations at two AACR special meetings and at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.

The company has also kept a foothold in the diagnostics space... 

In April 2024, it entered a co-development agreement with Marizyme, Inc. to provide up to $1.5 million to advance commercialization of the company’s first-in-class FDA cleared product, DuraGraft.

And in January, QLGN committed to participate in the 2025 bridge round of funding for NanoSynex, which is developing advanced Antimicrobial Susceptibility Testing (AST).

As you do your own homework on QLGN, be sure to check out the heavy-hitters on the company’s Scientific Advisory Board, this May 2024 investor presentation, and the company website.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: QLGN has had an awesome run over the past two weeks, despite market headwinds, and yesterday was especially great. 

I’m looking for the momentum to carry this one today and take us into the weekend on a high note.

Lock in to QLGN and let’s see what plays out!

To Your Success,

Jeff Bishop

P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now.

 

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

 

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from IR Agency for advertising Qualigen Therapeutics, Inc for a one day marketing program on March 28, 2025. It might seem obvious, but while our client claims not to own any shares in Qualigen Therapeutics, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Qualigen Therapeutics, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.